U.S. University Sets New Try For Hepatitis Drug In China
This article was originally published in PharmAsia News
Sometimes a scandal in one country, such as China, can have an impact on drug making a world away. University of Georgia researchers discovered the drug clevudine to treat hepatitis B, and the UGA Research Foundation plan to market it in China last year, potentially to treat a large volume of patients. But China's drug approval agency was hampered in its work as its former chief was tried, convicted and executed on bribery charges. The foundation took the drug to South Korea instead and saw $1.1 million in sales, its technology commercialization director reports. UGA had expected even more in China, but testing in China has resumed. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.